New data presented at AACE shows hypoglycemic events are less likely in patients with diabetes treated with an electronic glycemic management system.

Novo Nordisk announced positive results on its pipeline GLP-1 candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4 and 5.

In this Exclusive Interview, Dr. Joseph Aloi joins Diabetes in Control publisher Steve Freed for a discussion at the AACE 2016 convention in in Orlando, Florida, to discuss how software can help treat diabetic ketoacidosis.

This interview is also available as a video: click here to view. Dr. Joseph Aloi, Wake Forest Baptist Medical Center, Winston-Salem, NC. Steve: This is Steve Freed with Diabetes in Control and we’re here at AACE 2016 and we have with us a special guest who’s been working on some unique …

Guest article by David Kliff, Diabetic Investor: Panel further assessing date that SGLT-2 drug shows actual benefit for heart.

More stringent hyperglycemia management (target A1C 6-6.5%) in type 2 diabetes might be supported by which one of the following factors: A. Long-standing disease duration B. Moderate-severe vascular complications C. Shorter life expectancy D. Absent-few comorbidities Are you right? Follow the link to find out!

For many years, I have focused on aspects of lifestyle and health management that can enhance quality of life, especially when living with a chronic disease like diabetes, rather than simply on living a long time (longevity). Much of my motivation is derived from the personal experience of watching my maternal grandmother suffer through six (long) years of severe disability related to cardiovascular complications of diabetes starting at the age of 70 that left her unable to feed herself or communicate, bed bound, and with almost no quality of life for her final six years of life. Really, what is the point of simply being alive when you’re really not experiencing life under such conditions?

Challenge your Health IQ in this fun and educational health trivia app. Do you know the minimum SPF needed to protect yourself from the sun’s harmful rays? Or how many seconds you should wash your hands to kill germs? Test your Health IQ to see how your health skills stack up.

The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost-effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study published online by JAMA Ophthalmology.

In Part 4 of this Exclusive Interview, Dr. Joseph Aloi concludes his discussion with Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida with medical developments worth watching. Joseph Aloi, MD, is Section Chief of Endocrinology and Metabolism at Wake Forest Baptist Medical Center in …